| Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 20401474 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. The aim of this study was to gain a better understanding of the overall incidence and risk of significantly raised blood pressure in cancer patients who receive bevacizumab therapy. METHODS: We performed a meta-analysis of relevant randomized controlled trials (RCTs) identified in PubMed, Cochrane library, Embase, and American Society of Clinical Oncology conferences. Overall incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random-effects model. The primary clinical endpoint was significantly raised blood pressure (grade 3 or above). RESULTS: A total of 12,949 cancer patients with a variety of solid tumors from 19 RCTs were included in our meta-analysis. The overall incidence of significantly raised blood pressure was 8% (95% CI 6-10%) among patients receiving bevacizumab. Bevacizumab treatment was associated with a statistically significant increased risk of developing significantly raised blood pressure (RR 5.38, 95% CI 3.63-7.97). The RRs of significantly raised blood pressure in patients receiving bevacizumab at 5 and 2.5 mg/kg per week were 7.17 (95% CI, 3.91-13.13) and 4.11 (95% CI 2.49-6.78), respectively. Among cancer patients, those with renal cell carcinoma (RR 13.77, 95% CI 2.28-83.15) and breast cancer (RR 18.83, 95% CI 1.23-292.29) who received bevacizumab at 5 mg/kg per week had a higher risk of developing significantly raised blood pressure. CONCLUSIONS: Among the patients included in the trials analyzed in this meta-analysis, the addition of bevacizumab to cancer therapy treatments significantly increased the risk of significantly raised blood pressure. The risk may be dose-dependent and vary with tumor type. |
| | |
Authors:
|
Mao Mao An; Zui Zou; Hui Shen; Ping Liu; Meng Li Chen; Yong Bing Cao; Yuan Ying Jiang |
Related Documents
:
|
16880344 - Elevated blood pressure in adolescent boys predicts endothelial dysfunction: the cardio... 10898424 - Pulse pressure and risk for myocardial infarction and heart failure in the elderly. 16508574 - In a population-based prospective study, no association between high blood pressure and... 10619574 - Is high blood pressure a late manifestation of the hypertension syndrome? 10854004 - Effects of hormone replacement therapy on ambulatory blood pressure and vascular respon... 7572294 - Renovascular hypertension: a noninvasive screening approach using captopril renography. |
Publication Detail:
|
Type: Journal Article Date: 2010-04-17 |
Journal Detail:
|
Title: European journal of clinical pharmacology Volume: 66 ISSN: 1432-1041 ISO Abbreviation: Eur. J. Clin. Pharmacol. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-16 Completed Date: 2011-01-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1256165 Medline TA: Eur J Clin Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 813-21 Citation Subset: IM |
Affiliation:
|
R&D Center of New Drug, School of Pharmacy, Second Military Medical University, 325 Guo He Road, Shanghai 200433, People's Republic of China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects*,
therapeutic use Autonomic Nervous System Diseases / chemically induced, drug therapy, epidemiology* Breast Neoplasms / chemically induced, drug therapy Carcinoma, Renal Cell / chemically induced, drug therapy Cardiovascular Diseases / chemically induced, drug therapy, epidemiology* Female Humans Hypertension / chemically induced*, epidemiology, metabolism Incidence Meta-Analysis as Topic* Neoplasms / chemically induced, drug therapy* Randomized Controlled Trials as Topic Risk Factors Vascular Endothelial Growth Factor A / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Vascular Endothelial Growth Factor A; 0/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Social context influences recognition of bodily expressions.
Next Document: Aortic Calcification in a Patient With Hutchinson-Gilford Progeria Syndrome.